We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · January 23, 2020

Update on Tolerability and Overall Survival in COLUMBUS: Encorafenib + Binimetinib vs Vemurafenib or Encorafenib in BRAF V600–Mutant Melanoma

European Journal of Cancer

 

Additional Info

Disclosure statements are available on the authors' profiles:

European Journal of Cancer
Update on Tolerability and Overall Survival in COLUMBUS: Landmark Analysis of a Randomised Phase 3 Trial of Encorafenib Plus Binimetinib vs Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma
Eur. J. Cancer 2020 Feb 01;126(xx)33-44, PA Ascierto, R Dummer, JH Gogas, et al

Further Reading